ReviewBlood2015
How I treat acute lymphoblastic leukemia in older adolescents and young adults.
Review in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.
- Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations.American journal of hematology · 2026Guideline
- Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10/07.Blood cancer journal · 2020Trial
- Trial
- Causes of Inferior Outcome in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: Across Oncology Services and Regardless of Clinical Trial Enrollment.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018Trial
- [Multicenter clinical trial of acute lymphoblastic leukemia in elder children and adolescents].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2018Trial
- Navigating Asparaginase Treatment for Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations on the Role of Multidisciplinary Care.American journal of hematology · 2026Article
- Toxicity from asparaginase during acute lymphoblastic leukemia induction: a report from the Children's Oncology Group.Blood advances · 2026Article
- Community Experience With Pediatric-Inspired Regimens for Acute Lymphoblastic Leukemia in Adolescent and Young Adults.Cancer medicine · 2026Article
- Infectious complications in Philadelphia-Negative adolescent and young adult acute lymphoblastic leukemia patients in the era of pediatric-inspired regimen.Annals of medicine · 2025Article
- Real-world analysis of strategies to prevent thrombosis and bleeding in adults with ALL treated with asparaginase.Blood vessels, thrombosis & hemostasis · 2025Article
- Calaspargase pegol and pegaspargase cause similar hepatosteatosis in mice.Haematologica · 2025Article
- Quality of Life of Caregivers of Patients with Cancer: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2025Article
- Thromboprophylaxis with intermediate dose enoxaparin during asparaginase containing induction for young adults with acute lymphoblastic leukemia.Leukemia & lymphoma · 2025Article
- Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL.JCO oncology practice · 2024Article
- Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment.Hematology. American Society of Hematology. Education Program · 2023Article
- Initial Experiences in Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia/Lymphoma Treated with the Modified BFM 2002 Protocol in a Resource-Constrained Setting.South Asian journal of cancer · 2023Article
- Outcome of adolescents and young adults with acute lymphoblastic leukemia in a single center in Brazil.Hematology, transfusion and cell therapy · 2023Article
- Hematopoietic stem cell transplantation for acute lymphoblastic leukemia: why do adolescents and young adults outcomes differ from those of children? A retrospective study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC).Journal of cancer research and clinical oncology · 2023Article
- Abnormal expression ofBlood research · 2023Article
- Amino Acids in Cancer and Cachexia: An Integrated View.Cancers · 2022Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedDosage error in article text
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
At the intersection between children and older adults, the care of adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) poses unique challenges and issues beyond those faced by other age groups. Although the survival of AYA patients is inferior to younger children, growing evidence suggests that AYA patients have improved outcomes, with disease-free survival rates of 60% to 70%, when treated with pediatric-based approaches. A holistic approach, incorporating a multidisciplinary team, is a key component of successful treatment of these AYA patients. With the appropriate support and management of toxicities during and following treatment, these regimens are well tolerated in the AYA population. Even with the significant progress that has been made during the last decade, patients with persistence of minimal residual disease (MRD) during intensive therapy still have a poor prognosis. With new insights into disease pathogenesis in AYA ALL and the availability of disease-specific kinase inhibitors and novel targeted antibodies, future studies will focus on individualized therapy to eradicate MRD and result in further improvements in survival. This case-based review will discuss the biology, pharmacology, and psychosocial aspects of AYA patients with ALL, highlighting our current approach to the management of these unique patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.